Open Nav

Please submit your session questions in advance at

Caladrius Biosciences, Inc

  • David Mazzo, Caladrius Biosciences, Inc.

Caladrius is a clinical-stage biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Our current product candidates include two clinical-stage treatments for cardiovascular diseases based on our CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE designation, in Phase 2 testing in Japan and eligible for early conditional approval for the treatment of critical limb ischemia; and CLBS14, in Phase 2 testing for the treatment of coronary microvascular dysfunction and in late-stage clinical development for refractory angina for which it has received RMAT designation. Caladrius’ autoimmune product candidate in Phase 2 testing, CLBS03, is an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes. CLBS03 has been awarded Fast Track and Orphan designations by the FDA.

  • Date:Tuesday, February 12
  • Time:9:30 AM - 9:45 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23256
  • Goal for Presentation:Raise investor awareness
  • Company
  • Company HQ City:Basking Ridge
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Market Cap:$45 million
  • Ticker:CLBS
  • Exchange:NASDAQ
  • CEO/Top Company Official:Dr. David J. Mazzo
  • Year Founded:2006
  • Main Therapeutic Focus:Regenerative Medicine
  • Lead Product in Development:CD34
  • Development Phase of Primary Product:Phase III
David Mazzo
Caladrius Biosciences, Inc.